Swiss National Bank boosted its position in Luminex Co. (NASDAQ:LMNX) by 6.3% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 67,500 shares of the medical instruments supplier’s stock after buying an additional 4,000 shares during the quarter. Swiss National Bank owned approximately 0.15% of Luminex worth $1,330,000 as of its most recent filing with the SEC.
A number of other institutional investors have also recently made changes to their positions in the stock. Teacher Retirement System of Texas acquired a new stake in Luminex in the 4th quarter valued at approximately $270,000. American Century Companies Inc. grew its stake in Luminex by 221.5% in the fourth quarter. American Century Companies Inc. now owns 153,826 shares of the medical instruments supplier’s stock valued at $3,030,000 after purchasing an additional 105,979 shares in the last quarter. Aperio Group LLC grew its stake in Luminex by 7.9% in the fourth quarter. Aperio Group LLC now owns 34,333 shares of the medical instruments supplier’s stock valued at $676,000 after purchasing an additional 2,521 shares in the last quarter. Dupont Capital Management Corp bought a new position in Luminex in the fourth quarter valued at approximately $2,054,000. Finally, Cowen Prime Services LLC grew its stake in Luminex by 4.1% in the fourth quarter. Cowen Prime Services LLC now owns 246,962 shares of the medical instruments supplier’s stock valued at $4,865,000 after purchasing an additional 9,737 shares in the last quarter. 81.33% of the stock is currently owned by institutional investors and hedge funds.
Luminex Co. (NASDAQ:LMNX) opened at $21.55 on Wednesday. The firm has a market capitalization of $969.86, a P/E ratio of 26.48, a price-to-earnings-growth ratio of 2.10 and a beta of 0.16. Luminex Co. has a one year low of $17.70 and a one year high of $22.42.
The firm also recently announced a quarterly dividend, which will be paid on Friday, April 13th. Stockholders of record on Friday, March 23rd will be paid a dividend of $0.06 per share. The ex-dividend date of this dividend is Thursday, March 22nd. This represents a $0.24 annualized dividend and a dividend yield of 1.11%. Luminex’s dividend payout ratio is currently 35.82%.
In other news, Director G Walter Loewenbaum II sold 31,739 shares of Luminex stock in a transaction that occurred on Thursday, December 14th. The stock was sold at an average price of $20.49, for a total transaction of $650,332.11. Following the completion of the transaction, the director now directly owns 574,720 shares in the company, valued at approximately $11,776,012.80. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 6.90% of the company’s stock.
LMNX has been the subject of a number of analyst reports. BidaskClub downgraded Luminex from a “sell” rating to a “strong sell” rating in a research note on Wednesday, January 24th. BTIG Research initiated coverage on Luminex in a research note on Friday, January 5th. They issued a “buy” rating and a $24.00 price target for the company. Finally, William Blair restated a “market perform” rating on shares of Luminex in a research note on Tuesday, February 13th. Four investment analysts have rated the stock with a hold rating, one has issued a buy rating and one has given a strong buy rating to the company. The company has an average rating of “Buy” and an average price target of $22.33.
WARNING: “Swiss National Bank Purchases 4,000 Shares of Luminex Co. (LMNX)” was originally reported by American Banking News and is the sole property of of American Banking News. If you are reading this article on another website, it was illegally stolen and reposted in violation of United States & international copyright & trademark law. The correct version of this article can be read at https://www.americanbankingnews.com/2018/03/14/swiss-national-bank-purchases-4000-shares-of-luminex-co-lmnx.html.
Luminex Corporation develops, manufactures and sells biological testing technologies with applications throughout the diagnostics, pharmaceutical and life sciences industries. The Company’s products are focused on the molecular diagnostic testing market, which includes human genetics, personalized medicine and infectious disease segments.
Receive News & Ratings for Luminex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Luminex and related companies with MarketBeat.com's FREE daily email newsletter.